Barely Significant
← all excerpts

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.

Int J Mol Sci · 2021 · PMC7865398 · PMID 33513721

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendp > 0.05actually significant
The combined treatment group showed a trend toward greater tumor growth inhibition compared with belotecan or AZD6738 alone ( p > 0.05) ( Figure 5 b).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.